

Adele K Fielding

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4668018/publications.pdf>

Version: 2024-02-01

126
papers

9,672
citations

94269

37
h-index

37111

96
g-index

130
all docs

130
docs citations

130
times ranked

9145
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2017, 376, 836-847. | 13.9 | 1,443 |
| 2 | Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 57-66. | 5.1 | 1,031 |
| 3 | Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. <i>Blood</i> , 2007, 109, 944-950. | 0.6 | 716 |
| 4 | In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). <i>Blood</i> , 2008, 111, 1827-1833. | 0.6 | 702 |
| 5 | Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. <i>Blood</i> , 2007, 109, 3189-3197. | 0.6 | 655 |
| 6 | Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. <i>Nature</i> , 2007, 447, 966-971. | 13.7 | 355 |
| 7 | Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1795-1802. | 0.8 | 348 |
| 8 | T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). <i>Blood</i> , 2009, 114, 5136-5145. | 0.6 | 346 |
| 9 | UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. <i>Blood</i> , 2014, 123, 843-850. | 0.6 | 321 |
| 10 | Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. <i>Blood</i> , 2009, 113, 4489-4496. | 0.6 | 257 |
| 11 | Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age. <i>British Journal of Haematology</i> , 1997, 98, 512-519. | 1.2 | 230 |
| 12 | Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. <i>Blood</i> , 2001, 97, 3746-3754. | 0.6 | 223 |
| 13 | Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2016, 7, 13331. | 5.8 | 218 |
| 14 | Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. <i>British Journal of Haematology</i> , 2012, 157, 463-471. | 1.2 | 161 |
| 15 | International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. <i>Haematologica</i> , 2016, 101, 1524-1533. | 1.7 | 154 |
| 16 | Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress. <i>Blood</i> , 2019, 134, 1415-1429. | 0.6 | 148 |
| 17 | Minimal residual disease is a significant predictor of treatment failure in non-T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. <i>British Journal of Haematology</i> , 2010, 148, 80-89. | 1.2 | 147 |
| 18 | IGH@ Translocations, CRLF2 Dereglulation, and Microdeletions in Adolescents and Adults With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 3100-3108. | 0.8 | 120 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Donor Lymphocyte Infusions Modulate Relapse Risk in Mixed Chimeras and Induce Durable Salvage in Relapsed Patients After T-Cell-Depleted Allogeneic Transplantation for Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 971-978. | 0.8 | 117 |
| 20 | Strength of Envelope Protein Interaction Modulates Cytopathicity of Measles Virus. <i>Journal of Virology</i> , 2002, 76, 5051-5061. | 1.5 | 111 |
| 21 | Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 798-809. | 1.3 | 106 |
| 22 | <i>t(12;21)(p13;q22)</i> Translocations Are Prevalent in Teenagers and Young Adults With Acute Lymphoblastic Leukemia and Are Associated With a Poor Outcome. <i>Journal of Clinical Oncology</i> , 2014, 32, 1453-1462. | 0.8 | 87 |
| 23 | Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1739-1751. | 1.9 | 87 |
| 24 | An oncolytic measles virus engineered to enter cells through the CD20 antigen. <i>Molecular Therapy</i> , 2003, 7, 62-72. | 3.7 | 86 |
| 25 | Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression. <i>Cancer Research</i> , 2003, 63, 6463-8. | 0.4 | 82 |
| 26 | G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. <i>British Journal of Haematology</i> , 1997, 99, 933-938. | 1.2 | 70 |
| 27 | Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency. <i>Blood</i> , 2018, 131, 917-931. | 0.6 | 68 |
| 28 | Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. <i>Blood</i> , 2014, 123, 1327-1335. | 0.6 | 63 |
| 29 | Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2017, 129, 3221-3226. | 0.6 | 61 |
| 30 | Molecular classification improves risk assessment in adult <i>t(8;21)(p22;q22)</i> negative B-ALL. <i>Blood</i> , 2021, 138, 948-958. | 0.6 | 59 |
| 31 | Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. <i>Blood</i> , 2010, 115, 2763-2768. | 0.6 | 58 |
| 32 | Incidence and Dynamics of Epstein-Barr Virus Reactivation After Alemtuzumab-Based Conditioning for Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Transplantation</i> , 2010, 90, 564-570. | 0.5 | 57 |
| 33 | HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. <i>Blood</i> , 2010, 115, 5147-5153. | 0.6 | 56 |
| 34 | The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and <i>t(4;11)(q21;q23)/MLL-AFF1</i> prospectively treated in the UKALLXII/ECOG2993 trial. <i>Haematologica</i> , 2013, 98, 945-952. | 1.7 | 54 |
| 35 | A Hyperfusogenic Gibbon Ape Leukemia Envelope Glycoprotein: Targeting of a Cytotoxic Gene by Ligand Display. <i>Human Gene Therapy</i> , 2000, 11, 817-826. | 1.4 | 51 |
| 36 | Characterisation of the genomic landscape of <i>CRLF2</i> -rearranged acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 363-372. | 1.5 | 49 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA). <i>Blood</i> , 2015, 126, 679-679. | 0.6 | 39 |
| 38 | Measles as a potential oncolytic virus. <i>Reviews in Medical Virology</i> , 2005, 15, 135-142. | 3.9 | 38 |
| 39 | Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. <i>Haematologica</i> , 2009, 94, 1399-1406. | 1.7 | 34 |
| 40 | Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2013, 160, 640-648. | 1.2 | 33 |
| 41 | Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2010, 95, 8-12. | 1.7 | 26 |
| 42 | Impact of Pretransplantation 18 F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1234-1241. | 2.0 | 26 |
| 43 | Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study. <i>Leukemia</i> , 2022, 36, 625-636. | 3.3 | 25 |
| 44 | Mouse xenograft modeling of human adult acute lymphoblastic leukemia provides mechanistic insights into adult LIC biology. <i>Blood</i> , 2014, 124, 96-105. | 0.6 | 24 |
| 45 | Phase I Study of High-Stringency CD8 Depletion of Donor Leukocyte Infusions After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation</i> , 2009, 88, 1312-1318. | 0.5 | 23 |
| 46 | Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 594-602. | 1.4 | 23 |
| 47 | Differential Cytopathology and Kinetics of Measles Oncolysis in Two Primary B-cell Malignancies Provides Mechanistic Insights. <i>Molecular Therapy</i> , 2011, 19, 1034-1040. | 3.7 | 22 |
| 48 | JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 1929-1945. | 4.2 | 22 |
| 49 | Does Imatinib Change the Outcome in Philadelphia Chromosome Positive Acute Lymphoblastic Leukaemia in Adults? Data from the UKALLXII/ECOG2993 Study. <i>Blood</i> , 2007, 110, 8-8. | 0.6 | 22 |
| 50 | Attenuated, Oncolytic, but Not Wild-Type Measles Virus Infection Has Pleiotropic Effects on Human Neutrophil Function. <i>Journal of Immunology</i> , 2012, 188, 1002-1010. | 0.4 | 20 |
| 51 | Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement. <i>Seminars in Hematology</i> , 2020, 57, 142-148. | 1.8 | 20 |
| 52 | Type 1 Interferon Responses Underlie Tumor-Selective Replication of Oncolytic Measles Virus. <i>Molecular Therapy</i> , 2020, 28, 1043-1055. | 3.7 | 18 |
| 53 | Successful remission induction therapy with gilteritinib in a patient with <i>de novo</i> FLT3-mutated acute myeloid leukaemia and severe COVID-19. <i>British Journal of Haematology</i> , 2020, 190, e189-e191. | 1.2 | 17 |
| 54 | Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 3033-3037. | 2.5 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial. <i>Lancet Haematology</i> , 2022, 9, e262-e275. | 2.2 | 14 |
| 56 | Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial. <i>Blood</i> , 2010, 116, 169-169. | 0.6 | 13 |
| 57 | Philadelphia-Positive Acute Lymphoblastic Leukemia—Is Bone Marrow Transplant Still Necessary?. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S84-S88. | 2.0 | 12 |
| 58 | The Role of Neutrophils in Measles Virus—mediated Oncolysis Differs Between B-cell Malignancies and Is Not Always Enhanced by GCSF. <i>Molecular Therapy</i> , 2016, 24, 184-192. | 3.7 | 12 |
| 59 | Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 523-533. | 0.6 | 12 |
| 60 | Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative study. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072095500. | 1.1 | 12 |
| 61 | Single nucleotide polymorphism array-based signature of low hypodiploidy in acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 604-615. | 1.5 | 12 |
| 62 | Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7005-7005. | 0.8 | 12 |
| 63 | First Analysis of the UKALL14 Randomized Trial to Determine Whether the Addition of Nelarabine to Standard Chemotherapy Improves Event Free Survival in Adults with T-Cell Acute Lymphoblastic Leukaemia (CRUK/09/006). <i>Blood</i> , 2021, 138, 366-366. | 0.6 | 12 |
| 64 | In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial. <i>Lancet Haematology</i> , 2022, 9, e276-e288. | 2.2 | 12 |
| 65 | CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy. <i>Blood Advances</i> , 2020, 4, 4665-4668. | 2.5 | 11 |
| 66 | First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006). <i>Blood</i> , 2019, 134, 739-739. | 0.6 | 11 |
| 67 | Recent Developments in the Management of T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 160-169. | 1.2 | 10 |
| 68 | Antigen receptor gene rearrangements reflect on the heterogeneity of adult Acute Lymphoblastic Leukaemia (ALL) with implications of cell—origin of ALL subgroups — a UKALLXII study. <i>British Journal of Haematology</i> , 2010, 148, 394-401. | 1.2 | 9 |
| 69 | Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1834-1839. | 1.4 | 9 |
| 70 | Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity. <i>Frontiers in Pharmacology</i> , 2020, 11, 209. | 1.6 | 9 |
| 71 | Feasibility Of Pegylated-Asparaginase (PEG-ASP) During Induction In Adults With Acute Lymphoblastic Leukaemia (ALL): Results From The UK Phase 3 Multicentre Trial UKALL 14. <i>Blood</i> , 2013, 122, 3900-3900. | 0.6 | 9 |
| 72 | Fludarabine, Melphalan and Alemtuzumab Conditioned Reduced Intensity (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults Aged >40 Years with De Novo Acute Lymphoblastic Leukemia: A Prospective Study from the UKALL14 Trial (ISRCTN 66541317). <i>Blood</i> , 2015, 126, 733-733. | 0.6 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Response: Chemotherapy or allografting for young adults with high-risk ALL?. Blood, 2008, 111, 5755-5755. | 0.6 | 8 |
| 74 | In Adults with Standard-Risk Acute Lymphoblastic Leukemia (ALL) the Greatest Benefit Is Achieved from an Allogeneic Transplant in First Complete Remission (CR) and an Autologous Transplant Is Less Effective Than Conventional Consolidation/Maintenance Chemotherapy: Final Results of the International ALL Trial (MRC UKALL XII/ECOG E2993).. Blood, 2006, 108, 2-2. | 0.6 | 8 |
| 75 | Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. American Journal of Hematology, 2016, 91, 1107-1112. | 2.0 | 7 |
| 76 | <i>IKZF1</i> alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial. Blood Advances, 2021, 5, 3322-3332. | 2.5 | 7 |
| 77 | Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study. Frontiers in Pharmacology, 2020, 11, 1308. | 1.6 | 7 |
| 78 | Prognostic Impact of Chromosomal Abnormalities and Copy Number Alterations Among Adults with B-Cell Precursor Acute Lymphoblastic Leukaemia Treated on UKALL14. Blood, 2019, 134, 288-288. | 0.6 | 6 |
| 79 | Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference In Results Between B Cell Immunophenotypic Subgroups. Blood, 2010, 116, 524-524. | 0.6 | 6 |
| 80 | An Evaluation of Molecular Response in a Phase 2 Open-Label, Multicenter Confirmatory Study in Patients (pts) with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Receiving Treatment with the BiTE [®] Antibody Construct Blinatumomab. Blood, 2014, 124, 3704-3704. | 0.6 | 6 |
| 81 | Allogeneic Hematopoietic Stem Cell Transplantation Following Anti-CD19 BiTE [®] Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 965-965. | 0.6 | 6 |
| 82 | Development of a Novel Patient-Reported Outcome Measure in Haematological Malignancy for Use in Routine Clinical Practice: Item Generation. Blood, 2016, 128, 5985-5985. | 0.6 | 6 |
| 83 | SSBP2-CSF1R Is a Recurrent Fusion in B-Other Acute Lymphoblastic Leukaemia with Variable Clinical Outcome. Blood, 2014, 124, 3773-3773. | 0.6 | 5 |
| 84 | High Frequency and Poor Outcome of Ph-like Acute Lymphoblastic Leukemia in Adults. Blood, 2015, 126, 2618-2618. | 0.6 | 5 |
| 85 | Peripheral Blood Progenitor Cells Versus Bone Marrow. Stem Cells and Development, 1994, 3, 299-304. | 1.0 | 4 |
| 86 | Molecular Monitoring of Residual Disease (MRD) during Induction and Intensification Phases in Low Risk Adult B Cell ALL Treated According to the MRC UKALL12 Protocol.. Blood, 2005, 106, 1466-1466. | 0.6 | 4 |
| 87 | Comparative analysis of melphalan versus busulphan cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia. British Journal of Haematology, 2019, 187, e20-e24. | 1.2 | 3 |
| 88 | Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO. Frontiers in Pharmacology, 2020, 11, 571066. | 1.6 | 3 |
| 89 | Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial. Blood, 2010, 116, 493-493. | 0.6 | 3 |
| 90 | Antibody responses to SARS-CoV-2 vaccination in patients with acute myeloid leukaemia and high risk MDS on active anti-cancer therapies. British Journal of Haematology, 2022, 198, 478-481. | 1.2 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia – real-world resource use data. <i>Leukemia and Lymphoma</i> , 2020, 61, 491-493. | 0.6 | 2 |
| 92 | Utility of 18F-FDG-PET/CT in lymphoblastic lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1010-1012. | 0.6 | 2 |
| 93 | The Value of Molecular Monitoring for Residual Disease (MRD) in Early Morphological Remitters among Adults Diagnosed with B Cell ALL and Treated According to the MRC UKALL12 Protocol. <i>Blood</i> , 2005, 106, 1467-1467. | 0.6 | 2 |
| 94 | The Impact of Imatinib Therapy on Adult Philadelphia Positive Acute Lymphoblastic Leukaemia (ALL): Early Results from the UKALL12/ECOG 2993 Study. <i>Blood</i> , 2005, 106, 1839-1839. | 0.6 | 2 |
| 95 | Utility of FDG-PET/CT in Lymphoblastic Lymphoma. <i>Blood</i> , 2019, 134, 2890-2890. | 0.6 | 2 |
| 96 | En-Abl-ing treatment of ‘Ph-like’ ALL?. <i>Blood</i> , 2019, 134, 1277-1278. | 0.6 | 1 |
| 97 | Editors’ Introduction to special issue. <i>British Journal of Haematology</i> , 2020, 191, 519-520. | 1.2 | 1 |
| 98 | Single Nucleotide Polymorphism Array-Based Signature of Genetic Ploidy Groups in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 1473-1473. | 0.6 | 1 |
| 99 | Genetic and Genomic Characterisation of Older Adults with Acute Lymphoblastic Leukemia Treated on the UKALL14 and UKALL60+ Clinical Trials. <i>Blood</i> , 2019, 134, 2746-2746. | 0.6 | 1 |
| 100 | Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993). <i>Blood</i> , 2008, 112, 3314-3314. | 0.6 | 1 |
| 101 | Karyotype Is an Independent Prognostic Factor in Adult Acute Lymphoblastic Leukaemia (ALL): Analysis of Cytogenetic Data from 1,235 Patients on the Medical Research Council (MRC) UKALLXII /Eastern Cooperative Oncology Group (ECOG) 2993 Trial. <i>Blood</i> , 2005, 106, 331-331. | 0.6 | 1 |
| 102 | An Optimised In Vivo Modelling System For Adult Acute Lymphoblastic Leukaemia (ALL) Enables Sensitive Detection Of Leukaemia Initiating Cells (LIC) and Drug Resistant Clones. <i>Blood</i> , 2013, 122, 2641-2641. | 0.6 | 1 |
| 103 | Pre-Transplantation FDG-PET Predicts Early but Not Late Survival Outcomes Following Allogeneic Transplantation in Chemo-Sensitive Hodgkin Lymphoma. <i>Blood</i> , 2014, 124, 1225-1225. | 0.6 | 1 |
| 104 | Delays in Start of Intensification Therapy Are Common for Adults with Acute Lymphoblastic Leukemia, and Are Associated with Decreased Survival in Patients Who Undergo Allogeneic Stem Cell Transplant (SCT). <i>Blood</i> , 2014, 124, 208-208. | 0.6 | 1 |
| 105 | Final Development of the First Generic Quality of Life and Symptoms Measure Specific for Hematological Malignancies: The HM-PRO. <i>Blood</i> , 2019, 134, 3484-3484. | 0.6 | 1 |
| 106 | Acute lymphoblastic leukaemia (ALL) things come to those who wait: 60 years of progress in the treatment of adult ALL. <i>British Journal of Haematology</i> , 2020, 191, 558-561. | 1.2 | 1 |
| 107 | JAK-ing up treatment for CRLF2-R ALL. <i>Blood</i> , 2022, 139, 645-646. | 0.6 | 1 |
| 108 | Be careful what you wish for?. <i>Blood</i> , 2007, 109, 2673-2674. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Delays in Intensification are Common in Adults with Acute Lymphoblastic Leukemia (ALL), are Associated with Decreased Survival in Allogeneic Hematopoietic Cell Transplant (HCT) Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S176-S177. | 0.2 | 0 |
| 110 | 65. Oncolytic Measles Virus Differentially Affects Mitochondrial Biogenesis in Transformed versus Non-Transformed BM-Derived MSCs. <i>Molecular Therapy</i> , 2016, 24, S28-S29. | 3.7 | 0 |
| 111 | 663. Can Oncolytic Measles Virus Targeted to CD20 Recapitulate Any of the Effects of Rituximab in the Treatment of Acute Lymphoblastic Leukemia?. <i>Molecular Therapy</i> , 2016, 24, S262-S263. | 3.7 | 0 |
| 112 | ARF way to Ph+ ALL stratification?. <i>Blood</i> , 2018, 131, 1394-1395. | 0.6 | 0 |
| 113 | Value of Molecular Monitoring for Minimal Residual Disease Preceding Autologous SCT Following Diagnosis of B Cell Acute Lymphoblastic Leukemia in Patients Treated with the MRC UKALL12 Protocol.. <i>Blood</i> , 2005, 106, 1468-1468. | 0.6 | 0 |
| 114 | T-Cell Depleted Unrelated Donor Stem Cell Transplants Appear to Be of Value for Adult Philadelphia Chromosome Negative ALL Patients and Should Be Evaluated Prospectively in New Large Group Studies. <i>Blood</i> , 2008, 112, 4413-4413. | 0.6 | 0 |
| 115 | Attenuated Measles Virus: A Promising Therapeutic Modality for B Cell Malignancy.. <i>Blood</i> , 2009, 114, 2460-2460. | 0.6 | 0 |
| 116 | Vaccine Measles Virus Has Therapeutic Potential In B Cell Malignancy.. <i>Blood</i> , 2010, 116, 3757-3757. | 0.6 | 0 |
| 117 | Positive Pre-Transplantation [18-F] FDG-PET Is Not a Barrier to Successful Allograft Outcomes in Chemosensitive Hodgkin Lymphoma. <i>Blood</i> , 2011, 118, 2016-2016. | 0.6 | 0 |
| 118 | Biology and Outcome of 85 Adults with Acute Lymphoblastic Leukemia (ALL) with t(4;11)/MLL-AF4 Treated in the UKALL XII/ECOG 2993 Study. <i>Blood</i> , 2012, 120, 663-663. | 0.6 | 0 |
| 119 | Evaluation Of IKZF1 \hat{p} 4-7 Deletion As a Suitable Marker For Minimal Residual Disease Monitoring; A Study Of 161 Consecutive Acute Lymphoblastic Leukaemia (ALL) Patients On The On-Going UKALL14 Trial. <i>Blood</i> , 2013, 122, 1335-1335. | 0.6 | 0 |
| 120 | Barriers To Clinical Trial Enrolment For Teenagers and Young Adults With Acute Lymphoblastic Leukaemia: The Impact of Age Eligibility Criteria. <i>Blood</i> , 2013, 122, 1401-1401. | 0.6 | 0 |
| 121 | TP53 Alterations Are Frequent in Patients over 60 Years with B-Precursor Acute Lymphoblastic Leukemia (ALL) and Low Hypodiploid/Near Triploid (HoTr) Karyotype; They Correlate with RB1 Deletion and Leukemic Telomere Gain. <i>Blood</i> , 2014, 124, 3801-3801. | 0.6 | 0 |
| 122 | in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993. <i>Blood</i> , 2015, 126, 795-795. | 0.6 | 0 |
| 123 | Successful Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation in Adults with Inherited Primary Immunodeficiency (PID). <i>Blood</i> , 2016, 128, 4681-4681. | 0.6 | 0 |
| 124 | Activation of the LMO2 Oncogene in T-ALL through a Somatic Acquired Neomorphic Promoter. <i>Blood</i> , 2016, 128, 733-733. | 0.6 | 0 |
| 125 | Commonly Used Chemotherapy Drugs Differentially Determine Microenvironment-Mediated Protection, Via Mitochondrial Transfer, to B-Precursor Acute Lymphoblastic Leukaemia Cells. <i>Blood</i> , 2018, 132, 2690-2690. | 0.6 | 0 |
| 126 | Whole Genome Profiling of Adult B-Other Acute Lymphoblastic Leukaemia on the UKALL14 Trial. <i>Blood</i> , 2019, 134, 2743-2743. | 0.6 | 0 |